Thrombotic thrombocytopenic purpura (TTP): Why it’s important to understand it
In this episode of Lab Medicine Rounds, Dr. Marshall Mazepa, Assistant Professor of Medicine at the University of Minnesota, discusses the topic of thrombotic thrombocytopenic purpura (TTP) and why it’s important to understand it.
Lab Medicine Rounds · Mayo Clinic Laboratories
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Disclosure of relevant financial relationship: Dr. Mazepa received honoraria from Sanofi.
Timestamps:
00:00 Intro
00:52 Why is it important for physicians to have some understanding about TTP?
04:26 What’s new in this immune TTP area?
08:57 If you have a new patient show up, you do caplacizumab and plasma exchange together or are there certain patient populations, like certain characteristics who would or would not get this medication?
11:29 I was wondering if you could elaborate a little bit more about these chronic complications?
16:32 Do you think there is a role for repeat testing of ADAMTS13 on these patients in chronic phase, or is that an area that is unknown at this point?
18:53 What do you see on the horizon, what do you think the future looks like for TTP?
21:36 Outro
Resources:
Stroke and TTP (Hopkins group led by Dr. Shruti Chaturvedi): https://ashpublications.org/blood/article/134/13/1037/374919/Reduced-ADAMTS13-activity-during-TTP-remission-is
Cognitive impairment in TTP:
(Ohio State and London TTP group collaboration) https://ashpublications.org/blood/article/134/13/1037/374919/Reduced-ADAMTS13-activity-during-TTP-remission-is
(OK Registry, Dr. James George)